Canada Markets open in 3 hrs 7 mins
  • S&P/TSX

    18,861.36
    -217.24 (-1.14%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • DOW

    31,097.26
    +321.86 (+1.05%)
     
  • CAD/USD

    0.7785
    +0.0023 (+0.2982%)
     
  • CRUDE OIL

    108.02
    -0.41 (-0.38%)
     
  • BTC-CAD

    24,963.49
    +326.41 (+1.32%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • GOLD FUTURES

    1,805.70
    +4.20 (+0.23%)
     
  • RUSSELL 2000

    1,727.76
    +19.77 (+1.16%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,558.50
    -52.75 (-0.45%)
     
  • VOLATILITY

    26.70
    -2.01 (-7.00%)
     
  • FTSE

    7,242.96
    +74.31 (+1.04%)
     
  • NIKKEI 225

    26,153.81
    +218.19 (+0.84%)
     
  • CAD/EUR

    0.7448
    +0.0009 (+0.12%)
     

2 Cheap Tech Stocks to Buy After Their Impressive Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Written by Rajiv Nanjapla at The Motley Fool Canada

With inflation rising to multi-decade highs, the Federal Reserve of the United States has hiked interest rates. The federal agency could also increase interest rates further in the coming months. Higher interest rates could raise borrowing costs, thus hurting the margins of growth stocks, which require higher capital to fund their growth initiatives. Along with these concerns, the expectation of growth moderation and higher valuation has led to a selloff in growth stocks, which are trading at a substantial discount from their recent highs.

Meanwhile, I believe the correction in the following two tech stocks is overdone, proving excellent buying opportunities for long-term investors.

Nuvei

Nuvei (TSX:NVEI)(NASDAQ:NVEI) had reported a solid first-quarter performance earlier this month, with its top line growing by 43% to $214.5 million. The growth across all its four geographical segments drove its revenue. During the quarter, the company added new alternative payment methods to increase its count to over 550. It also expanded its digital payment and cryptocurrency solutions in North America while growing its customer base with the addition of new customers.

Along with top-line growth, the company’s adjusted net income grew by 35% to $69.1 million. It also generated a free cash flow of $82.5 million, representing year-over-year growth of 36%. It also closed the quarter with $735.0 million of cash. So, its liquidity position looks healthy.

The rising popularity of digital payments is expanding the addressable market for Nuvei. The expansion of the online gaming and sports betting market due to legalization and growth in crypto transactions could boost its financials in the coming years. Given the favourable market conditions, Nuvei’s management expects its revenue to grow by 30% in the medium term, while its adjusted EBITDA margin could reach 50% in the long run.

However, amid the recent selloff, Nuvei is trading at over a 68% discount from its September highs. Also, the correction has dragged its NTM price-to-sales multiple down to 6.2, making it an attractive buy.

WELL Health Technologies

WELL Health Technologies (TSX:WELL), which leverages technology to empower health practitioners to serve their patients better, reported a solid first-quarter performance earlier this week. Its revenue grew by 395% to $126.5 million, driven by acquisitions and organic growth.

During the quarter, its omnichannel patient visits increased by 62% to 772,093. Its combined patient visits, including that of MyHealth and Wisp, stood at 1,064,987 patients, representing an annualized run rate of 4.26 million. The revenue contribution from acquiring higher-margin CRH and MyHealth expanded its gross margins from 39.4% to 54.8%. Its adjusted EBITDA also increased from $0.5 million to $23.5 million. The company also posted an adjusted profit of $8.6 million compared to a net loss of $2.4 million in the previous year’s quarter.

With the increased adoption of telehealthcare services, I expect WELL Health’s financials to grow in the coming quarters. It has also ramped up its acquisition strategy and has signed multiple letters of intent. Given its growth initiatives, WELL Health’s management raised its 2022 revenue guidance from $500 million to $525 million. The management also expects its adjusted EBITDA to come around $100 million this year, with its net income to be in the positive territory.

Despite its healthy growth potential, the company trades at a discount of around 62% from its 52-week high. So, I believe long-term investors can accumulate the stock to earn superior returns.

The post 2 Cheap Tech Stocks to Buy After Their Impressive Earnings appeared first on The Motley Fool Canada.

Should You Invest $1,000 In Nuvei?

Before you consider Nuvei, we think you’ll want to hear this.

Our nearly S&P/TSX market doubling* Stock Advisor Canada team just released their top 10 starter stocks for 2022 that we believe could supercharge any portfolio.

Want to see if Nuvei made our list? Get started with Stock Advisor Canada today to receive all 10 of our starter stocks, a fully stocked treasure trove of industry reports, two brand-new stock recommendations every month, and much more.

See the 10 Stocks * Returns as of 4/14/22

More reading

The Motley Fool has positions in and recommends Nuvei Corporation. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

2022

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting